These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3878 related articles for article (PubMed ID: 15146294)

  • 41. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
    Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
    Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
    J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: differences from hydrocortisone-treated dendritic cells.
    Bellinghausen I; Brand U; Steinbrink K; Enk AH; Knop J; Saloga J
    J Allergy Clin Immunol; 2001 Aug; 108(2):242-9. PubMed ID: 11496241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
    Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
    J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production.
    Kim TS; DeKruyff RH; Rupper R; Maecker HT; Levy S; Umetsu DT
    J Immunol; 1997 May; 158(9):4137-44. PubMed ID: 9126973
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant gram-positive bacteria to CD4+ T lymphocytes.
    Corinti S; Medaglini D; Cavani A; Rescigno M; Pozzi G; Ricciardi-Castagnoli P; Girolomoni G
    J Immunol; 1999 Sep; 163(6):3029-36. PubMed ID: 10477566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide.
    Ikeuchi N; Futami J; Hosoi A; Noji S; Kurachi M; Ueha S; Fujii S; Yamada H; Matsushima K; Moriyasu F; Kakimi K
    Biochem Biophys Res Commun; 2010 Feb; 392(2):217-22. PubMed ID: 20067764
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
    Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
    Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates.
    Ju DW; Tao Q; Lou G; Bai M; He L; Yang Y; Cao X
    Cancer Res; 2001 May; 61(9):3735-40. PubMed ID: 11325846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling.
    Lindsay RW; Darrah PA; Quinn KM; Wille-Reece U; Mattei LM; Iwasaki A; Kasturi SP; Pulendran B; Gall JG; Spies AG; Seder RA
    J Immunol; 2010 Aug; 185(3):1513-21. PubMed ID: 20610651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.
    Pérez-Díez A; Butterfield LH; Li L; Chakraborty NG; Economou JS; Mukherji B
    Cancer Res; 1998 Dec; 58(23):5305-9. PubMed ID: 9850054
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo.
    Oldenhove G; de Heusch M; Urbain-Vansanten G; Urbain J; Maliszewski C; Leo O; Moser M
    J Exp Med; 2003 Jul; 198(2):259-66. PubMed ID: 12874259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Similar immune responses and antitumor effects of murine dendritic cells loaded with either exogenous or endogenous-synthesized protein.
    Lacave R; Masurier C; Guigon M; Lemoine FM; Klatzmann D; Colombo BM
    Int J Oncol; 2003 Dec; 23(6):1747-53. PubMed ID: 14612950
    [TBL] [Abstract][Full Text] [Related]  

  • 55. H2-M3-restricted CD8+ T cells augment CD4+ T-cell responses by promoting DC maturation.
    Chow MT; Teh HS
    Eur J Immunol; 2010 May; 40(5):1408-17. PubMed ID: 20162552
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state.
    Grohmann U; Bianchi R; Ayroldi E; Belladonna ML; Surace D; Fioretti MC; Puccetti P
    J Immunol; 1997 Apr; 158(8):3593-602. PubMed ID: 9103420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT; Umetsu DT; DeKruyff RH; Levy S
    J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IL-1 alpha and TNF-alpha are required for IL-12-induced development of Th1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice.
    Shibuya K; Robinson D; Zonin F; Hartley SB; Macatonia SE; Somoza C; Hunter CA; Murphy KM; O'Garra A
    J Immunol; 1998 Feb; 160(4):1708-16. PubMed ID: 9469428
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
    You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
    Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 194.